Lakefront Biotherapeutics - Sponsored ADR
LKFT Healthcare Biotechnology
Lakefront Biotherapeutics - Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $1.3 billion, up 321.9% from fiscal 2024. In the quarter to June 2026, revenue fell 95.4%, EPS grew 198.9% and free cash flow grew 18.2%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.
Follow LKFT
Lakefront Biotherapeutics - Sponsored ADR (LKFT) P/E ratio
Lakefront Biotherapeutics - Sponsored ADR has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 405× (November 2022) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 11.6× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 80.2× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
| FY2016 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Mar 2026 | 0.0× | — |
| Mar 2025 | 0.0× | — |
| Mar 2024 | 13.7× | — |
| Sep 2023 | 0.0× | — |
| 28 more quarters | Free account |
Against its own ten years
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| MRVI Maravai LifeSciences Holdings, Inc. compare | n/m |
| PHVS Pharvaris N.V. compare | n/m |
| MLYS Mineralys Therapeutics, Inc. compare | n/m |
| AGIO Agios Pharmaceuticals, Inc. compare | n/m |
| VERA Vera Therapeutics, Inc. compare | n/m |
| IMNM Immunome, Inc. compare | n/m |
| SRPT Sarepta Therapeutics, Inc. compare | n/m |
| LKFT Lakefront Biotherapeutics - Sponsored ADR | n/m |
| VCEL Vericel Corporation compare | 83.6× |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)